ATE495445T1 - Verfahren und zusammensetzungen in verbindung mit morbus alzheimer - Google Patents

Verfahren und zusammensetzungen in verbindung mit morbus alzheimer

Info

Publication number
ATE495445T1
ATE495445T1 AT05788728T AT05788728T ATE495445T1 AT E495445 T1 ATE495445 T1 AT E495445T1 AT 05788728 T AT05788728 T AT 05788728T AT 05788728 T AT05788728 T AT 05788728T AT E495445 T1 ATE495445 T1 AT E495445T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
methods
compositions related
proteins
Prior art date
Application number
AT05788728T
Other languages
German (de)
English (en)
Inventor
Jules Westbrook
Helen Byers
Malcolm Ward
Simon Lovestone
Abdul Hye
Stephen Lynham
Richard Joubert
Petra Prefot
Karsten Kuhn
Christian Baumann
Juergen Schaefer
Thorsten Prinz
Stefan Kienle
Original Assignee
Proteome Sciences Plc
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteome Sciences Plc, King S College London filed Critical Proteome Sciences Plc
Application granted granted Critical
Publication of ATE495445T1 publication Critical patent/ATE495445T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
AT05788728T 2004-09-29 2005-09-29 Verfahren und zusammensetzungen in verbindung mit morbus alzheimer ATE495445T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0421639.6A GB0421639D0 (en) 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease
PCT/GB2005/003756 WO2006035237A2 (en) 2004-09-29 2005-09-29 Methods and compositions relating to alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE495445T1 true ATE495445T1 (de) 2011-01-15

Family

ID=33397455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05788728T ATE495445T1 (de) 2004-09-29 2005-09-29 Verfahren und zusammensetzungen in verbindung mit morbus alzheimer

Country Status (10)

Country Link
US (2) US7897361B2 (cg-RX-API-DMAC7.html)
EP (3) EP1794594B1 (cg-RX-API-DMAC7.html)
JP (3) JP5483816B2 (cg-RX-API-DMAC7.html)
AT (1) ATE495445T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005288689B2 (cg-RX-API-DMAC7.html)
CA (1) CA2580532C (cg-RX-API-DMAC7.html)
DE (1) DE602005025897D1 (cg-RX-API-DMAC7.html)
DK (1) DK2354795T3 (cg-RX-API-DMAC7.html)
GB (1) GB0421639D0 (cg-RX-API-DMAC7.html)
WO (1) WO2006035237A2 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
GB0426859D0 (en) * 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
US20110263450A1 (en) * 2008-09-26 2011-10-27 The University Of Melbourne Alzheimer's disease biomarkers
IT1392551B1 (it) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
DK2389587T3 (en) 2009-01-26 2014-03-03 Electrophoretics Ltd Diagnostic and prognostic methods related Alzheimer's Disease
JP2010271078A (ja) 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
CA2709621A1 (en) * 2009-09-11 2011-03-11 Electrophoretics Limited Markers and methods relating to the assessment of alzheimer's disease
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP5906519B2 (ja) * 2011-09-13 2016-04-20 国立大学法人 熊本大学 二次元電気泳動による蛋白質の分離方法
EP2780690A4 (en) * 2011-11-18 2015-12-09 Alnylam Pharmaceuticals Inc QUANTIFICATION OF TRANSTHYRETIN AND ITS ISOFORMS
JP2015512877A (ja) 2012-02-22 2015-04-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌を治療するためのクラステリン阻害剤とｅｇｆｒ阻害剤の併用
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants
JP2015520123A (ja) 2012-03-29 2015-07-16 アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ， Ａ Ｂｏｄｙ Ｃｏｒｐｏｒａｔｅ Ｏｆ Ｔｈｅ Ｓｔａｔｅ Ｏｆ Ａｒｉｚｏｎａ Ａｃｔｉｎｇ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 個々のタンパク質バリアントに選択的な試薬を調製するナノスケールの方法
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
WO2013153461A2 (en) 2012-04-13 2013-10-17 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
US9678086B2 (en) 2012-09-10 2017-06-13 The Johns Hopkins University Diagnostic assay for Alzheimer's disease
US9891108B2 (en) 2012-10-03 2018-02-13 The Research Foundation For The State University Of New York Spectroscopic method for Alzheimer's disease diagnosis
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014133855A1 (en) * 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
GB201310203D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
GB201310150D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Methods and compositions relating to alzheimer's disease
JP6758184B2 (ja) * 2013-08-27 2020-09-23 シーアールシー・フォー・メンタル・ヘルス・リミテッドＣｒｃ Ｆｏｒ Ｍｅｎｔａｌ Ｈｅａｌｔｈ Ｌｔｄ 神経疾患のバイオマーカーを同定するための方法および神経疾患の診断
GB201322094D0 (en) 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
EP3092494A4 (en) * 2014-01-06 2017-10-18 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
US10639322B2 (en) * 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US9904961B2 (en) 2015-05-07 2018-02-27 Kuwait University System and method for determining the feedback capacity of information distributed in a complex network
JP6193942B2 (ja) * 2015-09-09 2017-09-06 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN105403649B (zh) * 2015-12-01 2018-03-20 深圳大学 一种检测ad的尿液多肽组ad生物标记物
JP6947450B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
EP3654032B1 (en) * 2017-07-14 2023-09-27 Mcbi Inc. Disease detection method
JP6408087B2 (ja) * 2017-07-25 2018-10-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
CN113024651A (zh) * 2019-12-25 2021-06-25 中国医学科学院药物研究所 阿尔茨海默病生物标志物及其应用
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
CN115808492A (zh) * 2021-09-14 2023-03-17 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物天冬酰胺及其应用
CA3268498A1 (en) * 2022-10-18 2024-04-25 Immungenetics Ag IDENTIFICATION OF A SUBJECT SUFFERING FROM ALZHEIMER'S DISEASE OR PRESENTING A RISK OF DEVELOPING ALZHEIMER'S DISEASE
CN117831756B (zh) * 2024-03-05 2024-06-28 精智未来(广州)智能科技有限公司 一种认知障碍的辅助分析方法、装置、设备及存储介质

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
US20030211622A1 (en) 1998-06-29 2003-11-13 Roberts L. Jackson Methods and compositions to assess oxidative brain injury
US20030131364A1 (en) 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
JP2001249128A (ja) * 2000-03-06 2001-09-14 Ikagaku:Kk 動脈硬化症またはアルツハイマー病の診断用キット
US20020174447A1 (en) 2001-01-23 2002-11-21 Greenspan Ralph J. Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease
US6528309B2 (en) * 2001-03-19 2003-03-04 The Regents Of The University Of California Vacuum-mediated desiccation protection of cells
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
AU2003253014A1 (en) * 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003245743A1 (en) * 2002-07-03 2004-01-23 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of tumor senescence genes
US7575929B2 (en) * 2002-10-02 2009-08-18 Dmi Life Sciences, Inc. Diagnosis of multiple sclerosis with diketopiperazines
WO2004074837A1 (en) * 2003-02-24 2004-09-02 Digitalbiotech Co., Ltd. Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer’s disease using same
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease

Also Published As

Publication number Publication date
WO2006035237A3 (en) 2006-08-03
US20080070995A1 (en) 2008-03-20
JP2008514946A (ja) 2008-05-08
DE602005025897D1 (de) 2011-02-24
JP2014209132A (ja) 2014-11-06
EP2354795A1 (en) 2011-08-10
AU2005288689A1 (en) 2006-04-06
US20110165146A1 (en) 2011-07-07
EP1794594B1 (en) 2011-01-12
US7897361B2 (en) 2011-03-01
GB0421639D0 (en) 2004-10-27
JP5893269B2 (ja) 2016-03-23
JP5483816B2 (ja) 2014-05-07
CA2580532C (en) 2019-06-25
AU2005288689B2 (en) 2011-10-27
JP2011209291A (ja) 2011-10-20
DK2354795T3 (en) 2015-02-16
CA2580532A1 (en) 2006-04-06
EP2354795B1 (en) 2014-12-17
EP2562545A1 (en) 2013-02-27
WO2006035237A2 (en) 2006-04-06
EP1794594A2 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
ATE495445T1 (de) Verfahren und zusammensetzungen in verbindung mit morbus alzheimer
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
EA200901373A1 (ru) Аминогетероциклические соединения
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
MY153979A (en) Substituted piperidino-dihydrothienopyrimidine
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
EA200401114A2 (ru) Замещённые гидроксиэтиламины
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
ZA200702318B (en) Nanobodies against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neual diseases such as alzheimer's disease
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
EP1758605A4 (en) PROUROGUANYLIN AS THERAPEUTIC AND DIAGNOSTIC AGENTS
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties